Spago Nanomedical
Sweden - LundBiotechnology
Focus: Tumor selective MRI agent; radionuclide cancer treatment
Spago Nanomedical is a life sciences company focused on Tumor selective MRI agent; radionuclide cancer treatment.
Profile data last refreshed Yesterday
Funding Stage
PUBLIC
Open Jobs
0
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
SN132D
Breast CancerClinical Trials (1)
NCT04080024A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer
Phase 1Help build intelligence for Spago Nanomedical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.